SCHEMBL7205634

SCHEMBL7205634

Cc1cccc(Oc2ccc(S(=O)(=O)C3CCN(C(N)=O)CC3(O)C(=O)O)cc2)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 8/20 0.55
MMP1 P03956 6/20 0.55
HTT P42858 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
FFAR1 O14842 1/20 0.41
PARP10 Q53GL7 4/20 0.39
PARP14 Q460N5 2/20 0.39
MMP2 P08253 2/20 0.39
MMP3 P08254 2/20 0.39
MMP9 P14780 2/20 0.39
MMP14 P50281 2/20 0.39
MMP12 P39900 1/20 0.39
S1PR2 O95136 1/20 0.38
F2 P00734 1/20 0.38
ADAMTS4 O75173 1/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7204271 0.91 MMP1 (0.45) MMP13MMP1PARP10PARP14MMP2
SCHEMBL7204562 0.90 MMP13 (0.51) MMP13MMP1HTTFFAR1MMP2
SCHEMBL7207163 0.90 MMP1 (0.45) MMP13MMP1HTTPARP10PARP14
SCHEMBL7207978 0.89 PARP10 (0.45) MMP13MMP1HTTPARP10PARP14
SCHEMBL7199646 0.89 MMP1 (0.43) MMP13MMP1HTTFFAR1PARP10
SCHEMBL7203058 0.86 MMP9 (0.47) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7208203 0.86 MMP13 (0.41) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7201801 0.86 MMP1 (0.57) MMP13MMP1FFAR1ADAMTS4
SCHEMBL7205956 0.86 MMP13 (0.53) MMP13MMP1
SCHEMBL7199692 0.84 PARP10 (0.41) MMP13MMP1PARP10PARP14MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP13 4/4885MMP1 8/4885HTT 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.